Climb Bio Statistics

Total Valuation

Climb Bio has a market cap or net worth of $110.46 million. The enterprise value is -$76.31 million.

Market Cap	110.46M
Enterprise Value	-76.31M

Important Dates

The last earnings date was Tuesday, August 12, 2025, before market open.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Climb Bio has 67.76 million shares outstanding. The number of shares has increased by 139.53% in one year.

Current Share Class	67.76M
Shares Outstanding	67.76M
Shares Change (YoY)	+139.53%
Shares Change (QoQ)	+0.18%
Owned by Insiders (%)	0.81%
Owned by Institutions (%)	27.51%
Float	25.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.59
P/TBV Ratio	0.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 14.08, with a Debt / Equity ratio of 0.00.

Current Ratio	14.08
Quick Ratio	13.65
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -22.92% and return on invested capital (ROIC) is -16.20%.

Return on Equity (ROE)	-22.92%
Return on Assets (ROA)	-15.83%
Return on Invested Capital (ROIC)	-16.20%
Return on Capital Employed (ROCE)	-28.46%
Revenue Per Employee	n/a
Profits Per Employee	-$2.60M
Employee Count	18
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -72.79% in the last 52 weeks. The beta is -0.10, so Climb Bio's price volatility has been lower than the market average.

Beta (5Y)	-0.10
52-Week Price Change	-72.79%
50-Day Moving Average	1.40
200-Day Moving Average	1.83
Relative Strength Index (RSI)	57.47
Average Volume (20 Days)	541,228

Short Selling Information

The latest short interest is 1.31 million, so 1.94% of the outstanding shares have been sold short.

Short Interest	1.31M
Short Previous Month	1.38M
Short % of Shares Out	1.94%
Short % of Float	5.17%
Short Ratio (days to cover)	14.68

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-52.98M
Pretax Income	n/a
Net Income	-46.76M
EBITDA	n/a
EBIT	-52.98M
Earnings Per Share (EPS)	-$0.69

Full Income Statement

Balance Sheet

The company has $84.70 million in cash and $639,000 in debt, giving a net cash position of $186.77 million or $2.76 per share.

Cash & Cash Equivalents	84.70M
Total Debt	639,000
Net Cash	186.77M
Net Cash Per Share	$2.76
Equity (Book Value)	185.76M
Book Value Per Share	2.74
Working Capital	81.18M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$39.66 million and capital expenditures -$77,000, giving a free cash flow of -$39.74 million.

Operating Cash Flow	-39.66M
Capital Expenditures	-77,000
Free Cash Flow	-39.74M
FCF Per Share	-$0.59

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Climb Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-139.53%
Shareholder Yield	-139.53%
Earnings Yield	-42.33%
FCF Yield	-35.97%

Analyst Forecast

The average price target for Climb Bio is $10.00, which is 513.50% higher than the current price. The consensus rating is "Buy".

Price Target	$10.00
Price Target Difference	513.50%
Analyst Consensus	Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1